Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease | Illinois

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--May 10, 2023--

Related Keywords

Italy ,Canada ,France ,United States ,Japan ,Mansfield ,Nunavut ,Tokyo ,Denmark ,Statesrobert Murphy ,Makoto Inoue ,Deborah Dunsire ,Statesdyana Lescohier ,Statesjeffrey Gilbert ,International Psychogeriatric Association ,Drug Administration ,Otsuka Pharmaceutical Development Commercialization Inc ,Otsuka Pharmaceutical Company Ltd ,Twitter ,Otsuka Holdings Co Ltd ,Linkedin ,Otsuka Pharmaceutical Co Ltd ,Ministry Of Health ,Corporate Communications ,National Pregnancy Registry For Atypical Antipsychotics ,Lundbeck ,European Medicines Agency ,Health Canada ,Otsuka America Pharmaceutical Inc ,New Drug Application ,Cohen Mansfield Agitation Inventory ,Agitation Associated ,Dementia Due ,National Pregnancy Registry ,Otsuka America Pharmaceutical ,Otsuka Pharmaceutical Development ,Otsuka Pharmaceutical Company ,Intj Geriatr Psychiatry ,United Statesrobert ,America Pharmaceutical ,United Statesjeffrey ,United Statesdyana ,Otsuka Pharmaceutical ,Business Wire ,Illinois ,